Please login to the form below

Not currently logged in

Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

She will succeed Jeffrey Chodakewitz

Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has appointed a new chief medical officer in the form of Reshma Kewalramani.

She succeeds Jeffrey Chodakewitz, who will remain at the company as a senior advisor through early 2019.

Jeffrey Leiden, chairman, president and chief executive officer of Vertex, said: “Reshma’s depth of medical knowledge, paired with her experience and proven track record as a clinical leader at Vertex, makes her an ideal successor to Jeff.

“I look forward to working with her to continue to advance our clinical development pipeline in cystic fibrosis and other serious diseases.”

Prior to joining the biotech, Kewalramani served as vice president, head of the US medical organisation at Amgen, where she spent 12 years in various capacities.

She said: “It’s a privilege to work at a company with such a relentless focus on science and deep commitment to improving the lives of patients and their families.

“I am excited to assume the role of CMO and continue our important work to help more people with cystic fibrosis and other serious diseases alongside the talented team at Vertex.”

6th March 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...